Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury

International Journal of Obesity

Volumn 36, Issue 8, 2012, Pages 1062-1071

  Tokuyama, H ^a   Wakino, S ^a   Hara, Y ^a   Washida, N ^a   Fujimura, K ^a   Hosoya, K ^a   Yoshioka, K ^a   Hasegawa, K ^a   Minakuchi, H ^a   Homma, K ^a   Hayashi, K ^a   Itoh, H ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

adipose tissue; aldosterone; MCP1; metabolic syndrome; SGK1

Indexed keywords

ALDOSTERONE; CHOLESTEROL; CREATININE; EPLERENONE; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR B; RHO FACTOR; RHO KINASE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOLOGY; INSULIN BLOOD LEVEL; KIDNEY; KIDNEY INJURY; KIDNEY PARENCHYMA; LIPID DIET; LOW FAT DIET; MALE; MESANGIUM CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; CHEMOKINE CCL2; DIET, FAT-RESTRICTED; DIET, HIGH-FAT; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OBESITY; OXIDATIVE STRESS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; SPIRONOLACTONE; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84864698384     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.232     Document Type: Article

References (49)

1. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? JAm Soc Nephrol 2004; 15: 2775-2791. (Pubitemid 41103387)
2. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217. (Pubitemid 32472634)
3. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22: 32-39. (Pubitemid 32126284)
4. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64: 2009-2019. (Pubitemid 37449535)
5. Wehrwein EA, Northcott CA, Loberg RD, Watts SW. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther 2004; 309: 1011-1019. (Pubitemid 38669686)
6. Nobes C, Hall A. Regulation and function of the Rho subfamily of small GTPases. Curr Opin Genet Dev 1994; 4: 77-81. (Pubitemid 24060299)
7. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem 1996; 120: 215-228. (Pubitemid 26335910)
8. Nakamura A, Hayashi K, Ozawa Y, Fujiwara K, Okubo K, Kanda T et al. Vessel-and vasoconstrictor-dependent role Rho/Rho-kinase in renal microvascular tone. J Vasc Res 2003; 40: 244-251. (Pubitemid 36980726)
9. Cavarape A, Endlich N, Assaloni R, Bartoli E, Steinhausen M, Parekh N et al. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 2003; 13: 37-45. (Pubitemid 36026295)
10. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 2006; 47: 1075-1083. (Pubitemid 44289164)
11. Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K et al. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008; 73: 826-834. (Pubitemid 351398286)
12. Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A. Active Rho kinase (ROK-alpha) associates with insulin receptorsubstrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem 2002; 277: 6214-6222. (Pubitemid 34968412)
13. Kanda T, Wakino S, Homma K, Yoshioka K, Tatematsu S, Hasegawa K et al. Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J 2006; 20: 169-171. (Pubitemid 43100503)
14. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/ salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800. (Pubitemid 36513325)
15. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-848. (Pubitemid 38405598)
16. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
17. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68. (Pubitemid 36056793)
18. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475. (Pubitemid 38608536)
19. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990-996. (Pubitemid 38479452)
20. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201. (Pubitemid 44141909)
21. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45: 538-544. (Pubitemid 40411256)
22. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T et al. Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J Am Soc Nephrol 2007; 18: 2054-2061. (Pubitemid 47041071)
23. Kelly DJ, Chanty A, Gow RM, Zhang Y, Gilbert RE. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointer-stitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005; 16: 1654-1660. (Pubitemid 41716471)
24. Zhou HR, Kim EK, Kim H, Claycombe KJ. Obesity-associated mouse adipose stem cell secretion of monocyte chemotactic protein-1. Am J Physiol Endocrinol Metab 2007; 293: E1153-E1158. (Pubitemid 350106580)
25. Yamashita K, Okuyama M, Nakagawa R, Honma S, Satoh F, Morimoto R et al. Development of sensitive derivatization method for aldosterone in liquid chromatography-electrospray ionization tandem mass spectrometry ofcorticos-teroids. J Chromatogr A 2008; 1200: 114-121.
26. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005; 46: 1039-1045.
27. Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M et al. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells. J Biol Chem 2001; 276: 47650-47657.
28. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
29. Zhou L, Yao X, Chen Y. Dexamethasone pretreatment attenuates lung and kidney injury in cholestatic rats induced by hepatic ischemia/reperfusion. Inflammation 2011; (in press).
30. Tatematsu S, Wakino S, Kanda T, Homma K, Yoshioka K, Hasegawa K et al. Role of nitric oxide-producing and-degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2007; 18: 741-749. (Pubitemid 46434491)
31. De Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-47. (Pubitemid 38031909)
32. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci 2001; 321: 242-248. (Pubitemid 32275933)
33. Greene EL, Kren S, HostetterTH. Role ofaldosterone in the remnant kidney model in the rat J Clin Invest 1996; 98: 1063-1068. (Pubitemid 26293326)
34. Chun TY, Chander P, Kim JW, Pratt JH, Stier CT. Aldosterone, but not angiotensin II, increased profibrotic factors in the kidney of adrenalectomized stroke prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab 2008; 295: E305-E312.
35. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 2006; 69: 1064-1072. (Pubitemid 43372182)
36. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles ofoxidative stress and Sgk1. Hypertension 2007; 49: 355-364. (Pubitemid 46143013)
37. Hou J, Speirs HJ, Seckl JR, Brown RW. Sgk1 gene expression in kidney and its regulation by aldosterone: spatio-temporal heterogeneity and quantitative analysis. J Am Soc Nephrol 2002; 13: 1190-1198. (Pubitemid 34441399)
38. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-1443. (Pubitemid 41291769)
39. Vallon V, Huang DY, Grahammer F, Wyatt AW, Osswald H, Wulff P et al. SGK1 as a determinant of kidney function and salt intake in response to mineralocorticoid excess. Am J Physiol Regul Integr Comp Physiol 2005; 289: R395-R401. (Pubitemid 41060493)
40. Hayashi K, Kanda T, Homma K, Tokuyama H, Okubo K, Takamatsu I et al. Altered renal microvascular response in Zucker obese rats. Metabolism 2002; 51: 1553-1561. (Pubitemid 36024125)
41. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263. (Pubitemid 37052371)
42. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-González G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) 2009; 71: 1-6.
43. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. Pathophysiological significanceoftheserum-and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006; 86: 1151-1178. (Pubitemid 44521650)
44. Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 2005; 96: 309-316. (Pubitemid 41080512)
45. Jeon JH, Kim KY, Kim JH, Baek A, Cho H, Lee YH et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008; 22: 1502-1511. (Pubitemid 351656790)
46. Sharpe CC, Hendry BM. Signaling. Focus on Rho in renal disease. JAm Soc Nephrol 2003; 14: 261-264.
47. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-1796. (Pubitemid 39141972)
48. Ozawa Y, Kobori H. Crucial role of Rho-nuclear factor-kappa B axis in angiotensin II-induced renal injury. Am J Physiol 2007; 293: F100-F109. (Pubitemid 47345008)
49. Hara Y, Wakino S, Tanabe Y, Saito M, Tokuyama H, Washida N et al. Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch. Sci Signal 2011; 25: ra3.